Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent prior to any study-related procedures being performed.~2. Is male or a non-pregnant, non-lactating female aged 18 years or older.~3. Willing and able to follow instructions and be present for the required study visits.~4. Have an Early Treatment Diabetic Retinopathy Study (ETDRS) Best Correct Visual Acuity (BCVA) of 20/200 or better in each eye.~5. Have an Intraocular Pressure (IOP) between 7 and 30 mmHg.~6. Certified as healthy by clinical assessment.~7. Verbal communication skills adequate to participate.~8. Able to tolerate bilateral instillation of Over-The-Counter artificial tear product based on investigator judgement.~Exclusion Criteria:~1. Have participated in an investigational study within the past 30 days.~2. Have a contraindication to local anesthetics.~3. Have known decreased corneal or conjunctival sensitivity.~4. Have had ocular surgery in either eye within the past 90 days.~5. Have had an intravitreal injection in either eye within 14 days.~6. Have ocular disease requiring punctual plugs or ocular inflammation.~7. Are currently using a systemic opioid or opiate analgesic or topical NSAID.~8. Cannot withhold their over the counter (OTC) artificial tear lubricant products for one hour preceding or following study medication.~9. Any condition, including alcohol or drug dependency, that would limit the subject's ability to comply with the procedures of the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AG-920 (Type: EXPERIMENTAL): Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).